222

ABBISKO CAYMAN LTD

No trades
See on Supercharts

2256 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The firm designed and developed a pipeline of fourteen candidates focused on oncology, including six candidates at clinical stage. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company was founded by Yao Chang Xu, Hong Ping Yu, and Zhui Chen on April 12, 2016 and is headquartered in Shanghai, China.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

2256 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company